Androgen receptor inhibitor

The results from the final analysis of the phase 3 TITAN study, which has demonstrated the continued statistically significant benefit...



Darolutamide ( Nubeqa ) is a structurally distinct androgen receptor inhibitor with a favorable safety profile, approved for treating men...


Genome-wide transcriptional analysis has identified a unique subset of androgen receptor (AR)+, estrogen receptor ( ER ) / progesterone receptor...


The European Commission ( EC ) has granted marketing authorisation for Erleada ( Apalutamide ), a next generation oral androgen...


The results from the phase 3 PROSPER trial in patients with non-metastatic ( M0 ) castration-resistant prostate cancer ( CRPC...


New findings were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium ( ASCO GU ) in San...


The results from the phase 2 TERRAIN trial of Enzalutamide ( Xtandi ) compared to Bicalutamide ( Casodex ) in...


The results from the STRIVE trial of Enzalutamide ( Xtandi ) compared to Bicalutamide ( Casodex ) in men with...


The androgen receptor inhibitor Enzalutamide ( Xtandi ) is approved for the treatment of metastatic castration-resistant prostate cancer that has...


The androgen receptor inhibitor, Enzalutamide ( Xtandi ) is approved for the treatment of metastatic castration-resistant prostate cancer that has...


A study, conducted by researchers at Dana-Farber Cancer Institute and AstraZeneca Pharmaceuticals, found that postmenopausal women with early-stage, hormone-sensitive...